2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione has been researched along with Supranuclear Palsy, Progressive in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Litvan, I | 1 |
| Aldrich, MS; Berent, S; Bluemlein, L; Foster, NL; White, RF | 1 |
1 review(s) available for 2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione and Supranuclear Palsy, Progressive
| Article | Year |
|---|---|
Cholinergic approaches to the treatment of progressive supranuclear palsy.
Topics: Cholinergic Agonists; Humans; Physostigmine; Succinimides; Supranuclear Palsy, Progressive | 1994 |
1 trial(s) available for 2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione and Supranuclear Palsy, Progressive
| Article | Year |
|---|---|
Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep.
Topics: Aged; Clinical Trials as Topic; Cognition; Female; Humans; Male; Middle Aged; Movement; Parasympathomimetics; Sleep; Succinimides; Supranuclear Palsy, Progressive | 1989 |